Cited by — Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema.
No admitted local citation edges point to this work yet.
